Fiche du document
2018
- doi: 10.1155/2018/7010196
- issn: 0278-0240
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1155/2018/7010196
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/29736194
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1875-8630
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_FE0BCCA11C689
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Dao Way (Chinese philosophy) illnessCiter ce document
N. Turck et al., « Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future. », Serveur académique Lausannois, ID : 10.1155/2018/7010196
Métriques
Partage / Export
Résumé
Thyroid-associated orbitopathy (TAO) is the most common autoimmune disease of the orbit. It occurs more often in patients presenting with hyperthyroidism, characteristic of Graves' disease, but may be associated with hypothyroidism or euthyroidism. The diagnosis of TAO is based on clinical orbital features, radiological criteria, and the potential association with thyroid disease. To date, there is no specific marker of the orbital disease, making the early diagnosis difficult, especially if the orbital involvement precedes the thyroid dysfunction. The goal of this review is to present the disease and combine the available data in the literature concerning investigation of TAO biomarkers. Despite the progress done in the understanding of TAO disease, some important pieces are still missing. Typically, for the future, major efforts have to be done in the discovery of new biomarkers, validation of the suspected candidates on multicenter cohorts with standardized methodologies, and establishment of their clinical performances on the specific clinical application fields in order to improve not only the management of the TAO patients but also the therapeutic options and follow-up.